You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

483 Results
Guidelines and Advice
Dec 1969
Document
Mar 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Drug
Other Name(s): Onureg®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Atezolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
amivantamab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2023
Document
Jul 2022
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Dec 1969
Statistical Reports
Statistical Reports
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2025

Pages